

ECTRIMS 2025: Spotlight on Early Use of High-Efficacy Therapies in MS

Key themes/insights from the conference



Shift toward early high-efficacy treatment (HET) – growing consensus among experts that initiating high-efficacy therapies, especially anti-CD20s, earlier in the disease course can slow progression and improve outcomes



Reassurance on safety – Long-term data support favorable safety profiles for anti-CD20s, reducing hesitation around early use

Insights from RxY data

Momentum lags actual prescribing behavior – Despite mounting evidence, real-world prescribing still skews toward later-line use, reflecting gaps in confidence, indication clarity, and perceptions of suitability for milder MS

- In RxY's 2025 data, anti-CD20 use among DMT-naïve patients declined slightly in both the US and EU5, while use in switch settings rose modestly. This shows that anti-CD20s remain largely reserved for later-line treatment in real-world practice



RxY MS US Study

Anti-CD20s Dynamic Patient Share

RxY MS EU5 Study

Anti-CD20s Dynamic Patient Share


■ 2024 ■ 2025



Physicians continue to view anti-CD20s as less suitable for milder or early-stage MS, citing limited indications and use cases. This uncertainty about their role in first-line treatment remains a key barrier to earlier adoption

Top Reasons Anti-CD20s Not Considered – RxY MS US W1 2025

% of verbatims




”

Limited indication/usage

"[Anti-CD20] is considered a more HIGHLY efficacious medication that I like to reserve more for advanced relapsing forms of MS. If used now, may not have much available for possibly later in her disease course"

Top Reasons Anti-CD20s Not Considered – RxY MS EU5 W1 2025


% of verbatims



Patient influence in treatment choice is rising, with nearly half of anti-CD20 prescriptions in the US and over one-third in the EU5 now patient-led, according to HCPs. In the EU5, patient voice is more influential in DMT-naïve patients compared to later line patients, signaling growing patient openness to early high-efficacy treatment use.

% Patient-led decisions among those prescribed Anti-CD20s – RxY MS US W1 2025

% Patient-led decisions among those prescribed Anti-CD20s – RxY MS EU5 W1 2025



Conclusions/Takeaways



Taken together, these findings illustrate the ongoing evolution of treatment practices. While clinical discourse increasingly supports early HET use, real-world prescribing remains more cautious.



HCPs continue to favor initiating HETs later in the disease journey, largely due to concerns about indication for early use and perceived suitability in patients with milder MS or lower disease activity.



At the same time, patients are becoming more active participants in treatment discussions and may be influencing some of the early adoption observed.

About RxY

RxY is a market research firm focusing on patient chart audit collection involving large samples of chart data from patients who experience treatment changes in near-real time, with rationale for treatment decision-making. RxY covers various therapy areas globally across dermatology, rheumatology, gastroenterology, hematology, oncology, neurology, and cardiometabolic. If you want to understand the true Why / Why Not behind consideration and prescribing of therapies please contact us.



RxY:
<https://www.rxyhc.com/>



Contact RxY:
<https://www.rxyhc.com/#ContactUs>

”

Limited indication/usage

“We prefer to use a slightly less effective treatment with the intention of reserving an anti-CD20 for cases of progression or an increase in inflammatory activity.”

